Psilocybin lowers inflammation markers in Parkinson's patients

Researchers at the University of California, San Francisco have demonstrated for the first time in humans that the psychedelic psilocybin can reduce inflammation markers. In a small pilot study with 12 participants with Parkinson's disease, five inflammatory signaling molecules were measured in the blood before and after two psilocybin sessions. Participants showed significantly lower inflammation markers after treatment, and this...